Brian E. Schwartz
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Hepatology 12
- Hepatocellular Carcinoma Treatment and Prognosis 7
- Liver physiology and pathology 6
-
- Lung Cancer Treatments and Mutations 10
- Co-authors
- Ronit Simantov (4 shared papers)Martin Eric Gore (3 shared papers)Tim G Eisen (3 shared papers)Walter Michael Stadler (2 shared papers)Apurva A. Desai (2 shared papers)Bernard J. Escudier (3 shared papers)Thomas E. Hutson (1 shared paper)Ronald M. Bukowski (1 shared paper)
- Journals
- Annals of Oncology (8 papers)Journal of Clinical Oncology (7 papers)British Journal of Cancer (7 papers)Clinical Cancer Research (5 papers)PLoS ONE (4 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Brian E. Schwartz
88 papers receiving 14.9k citations
Brian E. Schwartz's Hit Papers
Peers
Comparison fields: 5 of 135
- Hepatology 2.5k
- Cancer Research 2.5k
- Pulmonary and Respiratory Medicine 4.9k
- Oncology 4.1k
- Pathology and Forensic Medicine 1.8k
Countries citing papers authored by Brian E. Schwartz
This map shows the geographic impact of Brian E. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian E. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian E. Schwartz more than expected).
Fields of papers citing papers by Brian E. Schwartz
This network shows the impact of papers produced by Brian E. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian E. Schwartz. The network helps show where Brian E. Schwartz may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian E. Schwartz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4078 |
| 2 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Hit paper breakdown → | 2006 | 1551 |
| 3 | Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2006 | 1031 |
| 4 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 861 |
| 5 | Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors Hit paper breakdown → | 2004 | 765 |
| 6 | 2006 | 535 | |
| 7 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Hit paper breakdown → | 2012 | 485 |
| 8 | 2007 | 369 | |
| 9 | 2011 | 340 | |
| 10 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study Hit paper breakdown → | 2018 | 306 |
| 11 | Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma Hit paper breakdown → | 2018 | 298 |
| 12 | 2005 | 293 | |
| 13 | 2005 | 271 | |
| 14 | 2015 | 235 | |
| 15 | 2011 | 179 | |
| 16 | 2006 | 165 | |
| 17 | 2008 | 165 | |
| 18 | 2012 | 159 | |
| 19 | 2018 | 143 | |
| 20 | 2006 | 138 |
About Brian E. Schwartz
Brian E. Schwartz is a scholar working on Hepatology, Pulmonary and Respiratory Medicine, Genetics, Molecular Biology and Oncology, having authored 88 papers that have together received 15.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (11 papers), Lung Cancer Treatments and Mutations (10 papers), Melanoma and MAPK Pathways (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Chronic Lymphocytic Leukemia Research (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Liver physiology and pathology (6 papers) and Fibroblast Growth Factor Research (5 papers). The work is most often cited by research in Hepatology (2.5k citations), Cancer Research (2.5k citations), Pulmonary and Respiratory Medicine (4.9k citations), Oncology (4.1k citations) and Pathology and Forensic Medicine (1.8k citations). Brian E. Schwartz has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Ronit Simantov, Martin Eric Gore, Tim G Eisen, Walter Michael Stadler, Apurva A. Desai, Bernard J. Escudier, Thomas E. Hutson, Ronald M. Bukowski, Christine Chevreau and Sara M. Freeman. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, British Journal of Cancer, Clinical Cancer Research and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.